New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:01 EDTTEVATeva, OncoGenex say Phase III SYNERGY trial did not meet primary endpoint
Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer. Top-line survival results indicate the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic CRPC, compared to docetaxel/prednisone alone. “We are disappointed with these results. Addressing treatment resistance is critical in the fight against cancer. We are working with OncoGenex to more fully understand these data,” said Michael Hayden, MD, president of global R&D and chief scientific officer at Teva Pharmaceutical Industries Ltd. The adverse events observed for custirsen were similar to its known AE profile.
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
07:14 EDTTEVATeva August weekly volatility elevated into Q2 and outlook
Teva August weekly call option implied volatility is at 34, August is at 25, September and January is at 22; compared to its 26-week average of 27 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 31.
July 24, 2014
07:27 EDTTEVASome of Teva's biggest investors to vote against re-electing directors, WSJ says
Subscribe for More Information
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
July 23, 2014
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 16, 2014
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use